116 related articles for article (PubMed ID: 25821064)
1. Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment.
Gibiansky L; Giraudon M; Rayner CR; Brennan BJ; Subramoney V; Robson R; Kamal MA
J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):225-36. PubMed ID: 25821064
[TBL] [Abstract][Full Text] [Related]
2. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.
Kamal MA; Brennan BJ; Subramoney V; Lien YT; Morcos PN; Frey N; Rayner CR
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):326-36. PubMed ID: 27137141
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
Kamal MA; Van Wart SA; Rayner CR; Subramoney V; Reynolds DK; Bulik CC; Smith PF; Bhavnani SM; Ambrose PG; Forrest A
Antimicrob Agents Chemother; 2013 Aug; 57(8):3470-7. PubMed ID: 23669384
[TBL] [Abstract][Full Text] [Related]
4. Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
Reddy MB; Yang KH; Rao G; Rayner CR; Nie J; Pamulapati C; Marathe BM; Forrest A; Govorkova EA
PLoS One; 2015; 10(10):e0138069. PubMed ID: 26460484
[TBL] [Abstract][Full Text] [Related]
5. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
Parrott N; Davies B; Hoffmann G; Koerner A; Lave T; Prinssen E; Theogaraj E; Singer T
Clin Pharmacokinet; 2011 Sep; 50(9):613-23. PubMed ID: 21827216
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.
Brennan BJ; Davies B; Cirrincione-Dall G; Morcos PN; Beryozkina A; Chappey C; Aceves Baldó P; Lennon-Chrimes S; Rayner CR
Antimicrob Agents Chemother; 2012 Sep; 56(9):4729-37. PubMed ID: 22733065
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.
Pillai VC; Han K; Beigi RH; Hankins GD; Clark S; Hebert MF; Easterling TR; Zajicek A; Ren Z; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2015 Nov; 80(5):1042-50. PubMed ID: 26040405
[TBL] [Abstract][Full Text] [Related]
8. Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.
Kamal MA; Lien KY; Robson R; Subramoney V; Clinch B; Rayner CR; Gibiansky L
Antimicrob Agents Chemother; 2015 Nov; 59(11):6774-81. PubMed ID: 26282419
[TBL] [Abstract][Full Text] [Related]
9. Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
Chen Y; Ke M; Xu J; Lin C
AAPS PharmSciTech; 2020 Mar; 21(3):98. PubMed ID: 32128656
[TBL] [Abstract][Full Text] [Related]
10. A part-randomized study of intravenous oseltamivir in adolescents and adults.
Várkonyi I; Chappey C; Giraudon M; Burleigh L
Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1181-8. PubMed ID: 25678009
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
Davies BE
J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii5-ii10. PubMed ID: 20215135
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants.
Gibiansky L; Ravva P; Parrott NJ; Bhardwaj R; Zwanziger E; Grimsey P; Clinch B; Sturm S
Clin Pharmacol Ther; 2020 Jul; 108(1):126-135. PubMed ID: 31957010
[TBL] [Abstract][Full Text] [Related]
13. A physiologically-based pharmacokinetic model of oseltamivir phosphate and its carboxylate metabolite for rats and humans.
Gao G; Law F; Wong RNS; Mak NK; Yang MSM
ADMET DMPK; 2019; 7(1):22-43. PubMed ID: 35350745
[TBL] [Abstract][Full Text] [Related]
14. Study on the interaction of tamiflu and oseltamivir carboxylate with human serum albumin.
Nafisi S; Vishkaee TS
J Photochem Photobiol B; 2011 Oct; 105(1):34-9. PubMed ID: 21803598
[TBL] [Abstract][Full Text] [Related]
15. The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.
Kamal MA; Acosta EP; Kimberlin DW; Gibiansky L; Jester P; Niranjan V; Rath B; Clinch B; Sánchez PJ; Ampofo K; Whitley R; Rayner CR
Clin Pharmacol Ther; 2014 Sep; 96(3):380-9. PubMed ID: 24865390
[TBL] [Abstract][Full Text] [Related]
16. Oseltamivir-Current Dosing Recommendations Reduce the Therapeutic Benefit in Patients With Mild to Moderate Renal Function and/or Large Body Mass: A Review of the Literature With Recommendations to Optimize Dosing, Including the Use of Therapeutic Drug Monitoring.
Jones TE
Ther Drug Monit; 2021 Feb; 43(1):103-107. PubMed ID: 32947554
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis.
Patel K; Rayner CR; Giraudon M; Kamal MA; Morcos PN; Robson R; Kirkpatrick CM
Br J Clin Pharmacol; 2015 Apr; 79(4):624-35. PubMed ID: 25289522
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
19. Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population.
Huang H; Wang J; Li Q; Duan J; Yao Q; Zheng Q; Wang J; Wu D; Zhou Q; Tian Y; Zhang J
J Matern Fetal Neonatal Med; 2017 Jun; 30(11):1288-1292. PubMed ID: 27426925
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.
Chairat K; Jittamala P; Hanpithakpong W; Day NP; White NJ; Pukrittayakamee S; Tarning J
Br J Clin Pharmacol; 2016 Jun; 81(6):1103-12. PubMed ID: 26810861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
